A Multifactorial Mechanism in the Superior Antimalarial Activity of -C-GalCer
Figure 2
-C-GalCerโs superior therapeutic activity against malaria liver stages requires IL-12 and NK cells. (a) Groups of 5 WT or IL-12-deficient BALB/c mice were treated intraperitoneally (i.p.) with 1โg of either -C-GalCer or -GalCer or with nothing 3 days before challenge intravenously with live P. yoelii sporozoites, and then checked for malaria liver stage development. The results are expressed as the average SD of 5 mice. (b) Groups of 5 WT C57BL/6 mice were treated i.p. with PBS or anti-asialoGM1 antibody 1 day prior to i.p. injection with 1โg of -C-GalCer or -GalCer, or with nothing. Three days later the mice were challenged with live P. yoelii sporozoites, and then checked for malaria liver stage development. The results are expressed as the average SD of 5 mice. The data shown come from one of three experiments with similar results.
